Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the Results of the Phase 1\/2 Clinical Study of PCSK9 Antibody Tafolecimab at the ESC Annual Conference","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"LianBio","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$310.0 million","upfrontCash":"Undisclosed","newsHeadline":"LianBio Announces $310 Million Crossover Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"LianBio"},{"company":"Edding Pharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amarin Shares Topline Data from Partner\u2019s Pivotal Phase 3 Study of VASCEPA\u00ae (Icosapent Ethyl) in Mainland China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Edding Pharm"},{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent\u2019s Phase 3 CREDIT-2 Study of IBI306 Meets Primary Endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LianBio"},{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"LianBio","sponsor":"MyoKardia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LianBio"},{"company":"Innovent Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Innovent Biologics"},{"company":"LianBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"LianBio"}]

LianBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Details:

MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor approved by the U.S. FDA indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.

Lead Product(s): Mavacamten

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2022

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

Details:

The NDA submission was based on study results of three phase 3 trial compared with placebo, IBI306 (tafolecimab) injection reduced low-density lipoprotein cholesterol (LDL-C) levels by about 57% ~ 65%, and maintained long-term therapeutic efficacy.

Lead Product(s): Tafolecimab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2022

ASK
US

Upload
your Pipeline Activity

LianBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

Details:

MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor, that demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers.

Lead Product(s): Mavacamten

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: MyoKardia

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 09, 2022

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American Colle...

Details:

Results of study showed that both IBI306 150 mg Q2W or 450 mg Q4W yielded significant reduction in LDL-C levels in Chinese patients with HeFH, and Primary endpoint: IBI306 significantly reduced LDL-C levels for 150 mg Q2W; −61.9%, for 450 mg Q4W; P<0·0001 for both comparisons.

Lead Product(s): IBI306

Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2022

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

Details:

Primary endpoint met in two studies of recombinant full-human anti-PCSK-9 monoclonal antibody IBI306, CREDIT-1 study of non-FH patients at highcardiovascular risk, and CREDIT-4 study of patients with hypercholesterolemia significantly reduced compared with placebo.

Lead Product(s): Tafolecimab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2022

ASK
US

Upload
your Pipeline Activity

LianBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China

Details:

Mavacamten is a potential first-in-class, oral, allosteric modulator of cardiac myosin, under investigation for the treatment of conditions in which excessive cardiac contractility and impaired diastolic filling of the heart are the underlying cause.

Lead Product(s): Mavacamten

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 15, 2022

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent’s Phase 3 CREDIT-2 Study of IBI306 Meets Primary Endpoint

Details:

The CREDIT-2 study is a randomized, double-blind, placebo-controlled phase 3 study to evaluate the efficacy and safety of IBI306 in Chinese subjects with heterozygous familial hypercholesterolemia.

Lead Product(s): Tafolecimab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 12, 2021

ASK
US

Upload
your Pipeline Activity

Edding Pharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Amarin Shares Topline Data from Partner’s Pivotal Phase 3 Study of VASCEPA® (Icosapent Ethyl) in Mainland China

Details:

The study, investigating VASCEPA for patients with very high triglycerides, met its primary efficacy endpoint and showed safety profile similar to placebo. The findings are being prepared to support Edding’s dossier for seeking regulatory approval of VASCEPA in Mainland China.

Lead Product(s): Icosapent Ethyl

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 19, 2020

ASK
US

Upload
your Pipeline Activity

LianBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LianBio Announces $310 Million Crossover Financing

Details:

Proceeds will fund advancement of the Company’s global innovation mining platform and diversified portfolio of product candidates.

Lead Product(s): Mavacamten

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: RA Capital

Deal Size: $310.0 million Upfront Cash: Undisclosed

Deal Type: Financing October 29, 2020

ASK
US

Upload
your Pipeline Activity

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the ESC Annual Conference

Details:

Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab (IBI306) were successfully presented in the 2020 European Society of Cardiology (ESC) annual conference.

Lead Product(s): Tafolecimab

Therapeutic Area: Cardiology/Vascular Diseases Product Name: IBI306

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY